Closely held Cabaret Biotech said it had filed a preemptive lawsuit against
- Gilead, which exclusively licenses a patent from Cabaret for Yescarta in the field of oncology, has protested its royalty payment obligations since October 2018, according to
complaintfiled Monday in federal court in Wilmington, Delaware
- Cabaret is seeking a judgment that the patent isn’t invalid and that but for the license agreement, Yescarta infringes the patent, complaint says
- Kite paid licensing fees, royalties and milestone payments to Cabaret ...